 |
| 11-Mar-13 | Initiated |
Cantor Fitzgerald |
Buy |
$86 |
|
| 27-Feb-13 | Reiterated |
UBS |
Buy |
$64 → $67 |
|
| 23-May-12 | Initiated |
Oppenheimer |
Outperform |
$66 |
|
| 09-May-12 | Reiterated |
Mizuho |
Buy |
$75 → $80 |
|
| 02-May-12 | Reiterated |
Mizuho |
Buy |
$62 → $75 |
|
| 08-Dec-11 | Downgrade |
WBB Securities |
Buy → Hold |
$15 → $40 |
|
| 30-Sep-11 | Initiated |
Auriga |
Buy |
$55 |
|
| 03-Nov-10 | Downgrade |
WBB Securities |
Strong Buy → Buy |
$15 → $15 |
|
| 12-Oct-10 | Downgrade |
Jefferies |
Buy → Hold |
$11 → $11 |
|
| 01-Jul-10 | Upgrade |
WBB Securities |
Buy → Strong Buy |
$15 → $15 |
|
| 15-Jun-10 | Upgrade |
Barclays Capital |
Equal Weight → Overweight |
$12 → $15 |
|
| 17-May-10 | Initiated |
WBB Securities |
Buy |
$15 |
|
| 09-Dec-09 | Initiated |
Jefferies & Co |
Buy |
$11 |
|
| 26-Jun-09 | Downgrade |
Barclays Capital |
Overweight → Underweight |
|
|
| 17-Nov-08 | Reiterated |
Leerink Swann |
Mkt Perform |
$8.50 → $4.50 |
|
| 13-Nov-08 | Downgrade |
Argus |
Buy → Sell |
|
|
| 21-Aug-08 | Initiated |
Leerink Swann |
Mkt Perform |
|
|
| 11-Jul-07 | Initiated |
Lehman Brothers |
Overweight |
$27 |
|
| 11-Jul-07 | Initiated |
Credit Suisse |
Neutral |
|
|
|
|
| 21-May-13 05:10PM | Jazz Pharmaceuticals Public Limited Company Presents at UBS Global Healthcare Conference, May-21-2013 09:30 AM at Seeking Alpha |
| 03:46PM | Elan Provides Strategic Update Zacks |
| 20-May-13 11:00AM | FDA Accepts Actavis NDA Zacks |
| 16-May-13 01:53PM | 3 Value Investing Plays in Health Care at Motley Fool |
| 15-May-13 05:16PM | Good News for Novartis' Ilaris Zacks |
| 11:45AM | Nektar Posts Wider Loss, Maintains View Zacks |
| 11:40AM | Synergy Pharma Posts Wider Loss Zacks |
| 11:40AM | Dr. Reddy's Earnings Increase Y/Y Zacks |
| 10:45AM | 3 Stocks to Get on Your Watchlist at Motley Fool |
| 14-May-13 01:04PM | JAZZ PHARMACEUTICALS PLC Financials EDGAR Online Financials |
| 11:10AM | Forest-Trevena Ink Deal Zacks |
| 10:20AM | Jazz Pharma Posts Higher Y/Y Earnings Zacks |
| 13-May-13 09:30PM | Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events PR Newswire |
| 03:45PM | Teva - Alexza Sign Deal for Adasuve Zacks |
| 11:00AM | Lilly Scraps Oncology Candidate Zacks |
| 08:41AM | Narrower-than-Expected Loss at MannKind Zacks |
| 12-May-13 02:58PM | These 5 Stocks Saw Trading Price Swings This Past Week Post Earnings at Wall St. Cheat Sheet |
| 10-May-13 05:49PM | 3 Stocks to Buy on Wednesday's Post-Earnings Weakness at Motley Fool |
| 09-May-13 05:02PM | Jazz Pharmaceuticals Public's Earnings Beat Last Year's by 51% at Motley Fool |
| 08-May-13 04:12PM | Why Jazz Pharmaceuticals Shares Fell Out of Bed at Motley Fool -7.16% |
| 02:58PM | Stocks Near Intraday Highs In Late Trade; Toyota Up at Investor's Business Daily |
| 01:48PM | Stocks Up In Afternoon; Electronic Arts Hits New High at Investor's Business Daily |
| 01:07PM | Jazz sinks after CEO comment sparks generic concern at theflyonthewall.com |
| 01:03PM | 3 Stocks Pulling The Health Care Sector Downward at TheStreet |
| 12:25PM | Jazz Stock Falls As Competitive Fears Shadow Q1 Beat at Investor's Business Daily |
| 11:34AM | JAZZ Crosses Below Key Moving Average Level at TheStreet |
| 11:31AM | Jazz Pharma shares slide despite 1Q profit jump AP |
| 07-May-13 09:20PM | Jazz Pharmaceuticals Public Limited Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 05:22PM | Jazz Pharmaceuticals Earnings: Heres Why Investors are Happy Now at Wall St. Cheat Sheet |
| 04:30PM | Jazz Pharmaceuticals Earnings Call scheduled for 4:30 pm ET today CCBN |
| 04:27PM | InPlay: Jazz Pharma beats by $0.02, beats on revs; guides FY13 EPS above consensus, revs above consensus; authorized share repurchase of up to $200 million Briefing.com |
| 04:19PM | Jazz Pharmaceuticals Earnings Call scheduled for 4:30 pm ET today CCBN |
| 04:05PM | JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS PR Newswire |
| 11:27AM | Santarus Stock Lifts Off On Q1 Earnings, Guidance at Investor's Business Daily |
| 09:22AM | JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Pr EDGAR Online |
| 07:07AM | Q1 2013 Jazz Pharmaceuticals Earnings Release - After Market Close CCBN |
| 06-May-13 05:16PM | Jazz Pharmaceuticals Earnings Preview: Get Ahead of the Analysts at Wall St. Cheat Sheet |
| 02-May-13 12:43PM | Analysts: Facebook Concerns Are Unjustified and 2 Other Research Notes to Browse at Wall St. Cheat Sheet |
| 30-Apr-13 04:36PM | A Look at Biotechnologys Hot Name & Its Lack of Value at Motley Fool |
| 29-Apr-13 04:38PM | A Look at Biotechnologys Hot Name & Its Lack of Value at Motley Fool |
| 11:19AM | Unmet Medical Need in the Hepatitis C Space Creates Opportunities for Pharmaceutical and Biotech Companies: Disease Has High Number of Patients and Needs Curative Therapy with High Rate of Efficacy Wall Street Transcript |
| 28-Apr-13 05:07AM | Cramer's Mad Money - 16 Things To Watch In The Week Ahead (4/26/13) at Seeking Alpha |
| 26-Apr-13 06:45PM | Cramer's Homework Uncovers Stock Concerns at CNBC |
| 06:45PM | [video] You Ask, Cramer Answers! at CNBC |
| 11:50AM | William A. Hartman, President & Chief Executive Officer of Premier Biomedical, Inc. (BIEI), Interviews with The Wall Street Transcript Wall Street Transcript |
| 25-Apr-13 04:13PM | New KKR payout policy buoys investors, profit tops view Reuters |
| 12:18PM | UPDATE 1-New KKR payout policy buoys investors, profit tops view at Reuters |
| 10:31AM | [$$] KKR Rides Stock-Market Surge at The Wall Street Journal |
| 10:09AM | [$$] KKR Rides Stock-Market Surge at The Wall Street Journal |
| 08:36AM | [$$] Broad Measure of KKR's Earnings Falls at The Wall Street Journal |
| 08:01AM | KKR's earnings drop on slower fund appreciation at Reuters |
| 24-Apr-13 05:40PM | Jazz Pharmaceuticals, MercadoLibre Hover Near Highs at Investor's Business Daily |
| 23-Apr-13 04:05PM | Jazz Pharmaceuticals To Report First Quarter 2013 Financial Results On May 7, 2013 PR Newswire |
| 17-Apr-13 04:25PM | Jazz Rises On Unusually High Volume (JAZZ) at TheStreet |
| 16-Apr-13 08:47AM | Does JAZZ Have Any Pizzazz Left? at Seeking Alpha |
| 15-Apr-13 11:12PM | JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events EDGAR Online |
| 07:31PM | Peter Lynch's GARP Stocks at Motley Fool |
| 13-Apr-13 09:39AM | Acorda: A Biotech Company To Consider at Seeking Alpha |
| 01-Apr-13 07:48PM | ISM Leads Market Down Bearish Path at Seeking Alpha |
| 27-Mar-13 05:02PM | Jazz Pharmaceuticals Larger Than S&P 500 Component WPX Energy at Forbes |
| 03:07AM | Big move expected from Jazz Pharma optionMONSTER |
| 02:43AM | Big move expected from Jazz Pharma optionMONSTER |
| 02:13AM | Big move expected from Jazz Pharma optionMONSTER |
| 19-Mar-13 06:40PM | [video] Lightning Round at CNBC |
| 06:36PM | Lightning Round: Cypress Semi, Stewart, Jazz Pharma and More at CNBC |
| 15-Mar-13 08:05AM | Lithia, LinkedIn Among Top 5 With Rising Estimates at Investor's Business Daily |
| 14-Mar-13 06:09PM | [$$] A Pharma Stock Hits the High Notes at Barrons.com |
| 05:00PM | 4 Healthcare Stock Stories to Ignite Investor Chatter at Wall St. Cheat Sheet |
| 13-Mar-13 10:05AM | In Insider Trading, Carl Icahn Again Increases His Stake in Herbalife, While KKR Sells Shares of Jazz Pharmaceuticals at Minyanville |
| 12-Mar-13 04:35PM | Stocks End Mixed As Volume Rises; Yandex, U.S. Silica Dive at Investor's Business Daily |
| 01:41PM | Stocks Down Modestly In Afternoon; U.S. Silica Dives at Investor's Business Daily |
| 12:02PM | Jazz Pharmaceuticals Public Limited Company Presents at Barclays Global Healthcare Conference, Mar-12-2013 09:00 AM at Seeking Alpha |
| 11:57AM | Charting the S&Ps test of record territory at MarketWatch |
| 10:01AM | On The Fly: Analyst Initiation Summary theflyonthewall.com |
| 11-Mar-13 02:45PM | Jazz Pharma is a Buy and 3 More Analyst Opinions to Read Now at Wall St. Cheat Sheet |
| 01:49PM | Wall Street Mixed In Afternoon; Abaxis Hits New High at Investor's Business Daily |
| 10:11AM | On The Fly: Analyst Initiation Summary theflyonthewall.com |
| 09:41AM | Jazz Pharmaceuticals: Playing A Sweet Song For Growth Investors at Seeking Alpha |
| 09:24AM | Which White-Hot Drug Stocks Have the Strongest Earnings Trends? at Wall St. Cheat Sheet |
| 09:16AM | New Stock Coverage: Jazz Pharmaceuticals Going for a Song at Minyanville |
| 08:45AM | Analysts' Actions: BTU JAZZ MYL SKUL TDG TheStreet |
| 10-Mar-13 11:40PM | Coverage initiated on Jazz Pharma by Cantor Fitzgerald Briefing.com |
| 07-Mar-13 12:08PM | Land JAZZ Even Cheaper Than Its Secondary? at Forbes |
| 06-Mar-13 04:17PM | JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 05-Mar-13 01:54PM | Stocks Hold Onto Morning Gains; OpenTable At New High at Investor's Business Daily |
| 01:04PM | JAZZ PHARMACEUTICALS PLC Financials EDGAR Online Financials |
| 12:48PM | JAZZ Beats EPS, Misses Sales Zacks |
| 09:05AM | Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders PR Newswire |
| 07:44AM | Early Movers: JCP, DELL, NFLX & More at CNBC |
| 04-Mar-13 04:47PM | InPlay: Jazz Pharma announces public offering of 5.375 mln ordinary shares by selling shareholders Briefing.com |
| 04:45PM | Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders PR Newswire |
| 04:40PM | JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 03-Mar-13 09:57AM | Which of These 5 Pharma Stocks have the Strongest Earnings Trends? at Wall St. Cheat Sheet |
| 04:16AM | Jazz Pharmaceuticals: Music To Our Ears at Seeking Alpha |
| 01-Mar-13 01:18PM | 3 Stocks Set to Soar at Motley Fool |
| 27-Feb-13 07:30PM | New Star Analyst Rankings for Jazz Pharmaceuticals plc StarMine |
| 03:21PM | Concert harmonizes with with Jazz on $120M drug deal at bizjournals.com |
| 02:31PM | 3 Biotech Stocks Rising on Big Volume at TheStreet |
| 10:48AM | Zynga Risk/Reward Seen as Favorable and 4 Stock Analyses Turning Heads at Wall St. Cheat Sheet |
| 09:27AM | Acquisitions help Jazz Pharma 4Q profit soar AP |
|
|
| Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD, which are orally disintegrating clozapine tablets for the resistant schizophrenia treatment. It also provides Luvox CR to treat obsessive compulsive disorder; Versacloz oral suspension; Caphosol to treat oral mucositis; Quadramet for the treatment of pain in patients whose cancer has spread to the bones; ProstaScint for imaging the extent and spread of prostate cancer; Niravam for the treatment of generalized anxiety and panic disorders; and Parcopa for the symptoms associated with idiopathic Parkinson's disease treatment. In addition, the company offers Collatamp, a surgical implant impregnated with the antibiotic gentamicin; Fomepizole to treat ethylene glycol poisoning; Kidrolase for treating ALL, Leukaemic meningitis, and non-Hodgkin's lymphoma; Xenazine to treat movement disorders associated with Huntington's chorea and hemiballismus; and Custodiol, a ready to use solution used in organ transplantation. Further, it develops Asparec, a pegylated recombinant Erwinia asparaginase that is in Phase I clinical trials for the treatment of patients with ALL with E. coli asparaginase hypersensitivity; and Leukotac, an anti-CD25 monoclonal antibody is in Phase III clinical trials for the treatment of steroid-refractory acute graft vs. host diseases. The company markets its products through its sales representatives, distributors, and wholesalers, as well as through third party vendors. Jazz Pharmaceuticals Public Limited Company is headquartered in Dublin, Ireland. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| COZADD BRUCE C | Chairman and CEO | May 14 | Sale | 58.52 | 4,000 | 234,080 | 661,643 | May 15 07:45 PM | | COZADD BRUCE C | Chairman and CEO | May 03 | Sale | 60.00 | 1,000 | 60,000 | 665,643 | May 06 05:40 PM | | COZADD BRUCE C | Chairman and CEO | Apr 09 | Sale | 54.52 | 4,000 | 218,080 | 666,643 | Apr 11 09:11 PM | | COZADD BRUCE C | Chairman and CEO | Mar 21 | Option Exercise | 19.90 | 48,482 | 964,761 | 670,643 | Mar 22 07:13 PM | | COZADD BRUCE C | Chairman and CEO | Mar 12 | Sale | 59.58 | 5,000 | 297,920 | 622,161 | Mar 12 08:08 PM | | O'Keefe Kenneth W | Director | Mar 08 | Sale | 58.28 | 400,000 | 23,312,000 | 261,212 | Mar 12 11:00 AM | | KKR JP III LLC | 10% Owner | Mar 08 | Sale | 58.28 | 3,750,000 | 218,550,000 | 7,888 | Mar 12 05:29 PM | | KKR Fund Holdings L.P. | 10% Owner | Mar 08 | Sale | 58.28 | 3,750,000 | 218,550,000 | 7,888 | Mar 12 05:28 PM | | FALBERG KATHRYN E | EVP and CFO | Mar 05 | Option Exercise | 7.35 | 44,216 | 324,988 | 133,417 | Mar 05 07:10 PM | | COZADD BRUCE C | Chairman and CEO | Mar 04 | Sale | 60.00 | 1,000 | 60,000 | 577,161 | Mar 06 08:35 PM | | ENRIGHT PATRICK G | Director | Feb 19 | Sale | 58.13 | 47,372 | 2,753,621 | 31,142 | Feb 20 08:19 PM | | ENRIGHT PATRICK G | Director | Feb 15 | Sale | 58.42 | 19,278 | 1,126,189 | 32,063 | Feb 20 08:19 PM | | COZADD BRUCE C | Chairman and CEO | Feb 12 | Sale | 56.23 | 4,000 | 224,920 | 578,161 | Feb 13 04:32 PM | | ENRIGHT PATRICK G | Director | Jan 15 | Sale | 56.72 | 23,228 | 1,317,534 | 32,442 | Jan 16 04:29 PM | | ENRIGHT PATRICK G | Director | Jan 11 | Sale | 56.54 | 1,600 | 90,463 | 32,898 | Jan 14 06:46 PM | | ENRIGHT PATRICK G | Director | Jan 10 | Sale | 56.52 | 35,922 | 2,030,470 | 32,929 | Jan 11 04:36 PM | | ENRIGHT PATRICK G | Director | Jan 09 | Sale | 56.52 | 5,900 | 333,447 | 33,635 | Jan 11 04:36 PM | | COZADD BRUCE C | Chairman and CEO | Jan 08 | Sale | 55.60 | 4,000 | 222,400 | 582,161 | Jan 10 04:39 PM | | COZADD BRUCE C | Chairman and CEO | Dec 11 | Sale | 50.55 | 4,000 | 202,200 | 586,161 | Dec 13 04:34 PM | | COZADD BRUCE C | Chairman and CEO | Nov 13 | Sale | 51.11 | 4,000 | 204,440 | 589,662 | Nov 15 04:02 PM | | COZADD BRUCE C | Chairman and CEO | Oct 09 | Sale | 56.69 | 4,000 | 226,760 | 593,662 | Oct 11 04:46 PM | | ENRIGHT PATRICK G | Director | Oct 02 | Sale | 58.63 | 66,650 | 3,907,709 | 33,752 | Oct 04 03:26 PM | | Cox Russell J. | EVP & Chief Commercial Officer | Oct 01 | Sale | 57.24 | 5,000 | 286,200 | 45,012 | Oct 03 04:14 PM | | O'Keefe Kenneth W | Director | Aug 30 | Sale | 45.32 | 200,000 | 9,064,000 | 661,212 | Aug 31 06:46 PM | | FALBERG KATHRYN E | EVP and CFO | Aug 16 | Sale | 47.57 | 53,000 | 2,521,210 | 0 | Aug 17 08:31 PM | | FALBERG KATHRYN E | EVP and CFO | Aug 16 | Sale | 47.48 | 7,000 | 332,360 | 88,782 | Aug 17 08:31 PM |
|
|
|
|
|
|
